CTRI/2018/02/011935已完成4 期
An Open Label, Single arm, Observational Study to Evaluate the Efficacy, Safety & Tolerability of Ketoconazole 2 % in Combination With Beclomethasone 0.025% in Patients With Tinea and sebaceous dermatitisInfections
Med Manor Organics Pvt ltd0 个研究点目标入组 30 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Subjects with tinea infections who are either treatment naive or were not on any treatment for at-least 3 months
- •2.Have a clinical diagnosis of uncomplicated interdigital Tinea pedis confirmed by KOH microscopy
- •3.Subjects aged 12 to 75 years with Tinea Infections
- •4.Subjects with Epidermal type of Tinea infections
- •5.Subjects willing to return for all clinic visits and complete all study-related procedures
排除标准
- •1.Subjects with dermal or any other type of fungal infections other than epidermal type
- •2.Subjects who are either pregnant or breast feeding
- •3.Have a previous sensitivity to imidazole antifungal agents or to any ingredient of the study medication
- •4.Subjects taking any other form of alternative treatment like ayurvedic etc.. for fungal infections
- •5.Subjects known to have hypersensitivity to any of the ingredients of the formulation
研究者
相似试验
已完成
4 期
Observational Study to Evaluate Efficacy, Safety and Tolerability of Z-n-butylresorcinol in Patients with MelasmaCTRI/2015/04/005697Micro Labs Ltd50
已完成
不适用
Clinical trial on back pain on their sleep qualityCTRI/2019/12/022519Amazon Development Centre India Pvt Ltd
尚未招募
4 期
observational study to evaluate the safety, efficacy andtolerability of VASOCLEAR syrup in patients withcardio vascular problemsCTRI/2017/06/008818RATHNA BIOTECK PvtLtd40
Unknown
2 期
Clinical study of Anti Hangover Drink NE-A01 in Reducing Alcohol Induced Hangover Symptoms in Adult Male Social Drinkers.CTRI/2019/05/018976aturedge Beverages Pvt Ltd
已完成
2 期
A study to evaluate the efficacy, safety and tolerability of tacrolimus ointment 0.1% in patients of oral lichen planusCTRI/2015/09/006211Intas Pharmaceuticals Ltd30
